002099.SZ
海翔药业
SZSE · Healthcare · C 制造业 · CN
CNY 5.05
−3.63%Aug 28, 2026, 08:16 UTC
Haixiang Pharmaceutical reported a net loss of 64.038 million yuan for the first half of 2026, turning from a profit in the same period last year.
Source:Aug 26, 2026, 08:20 UTC
Haixiang Pharmaceutical's wholly-owned subsidiary Zhejiang Haixiang Chuannan Pharmaceutical received approval from China's National Medical Products Administration for its adenosine cyclophosphate API, packaged in 4kg/drum, with registration approved but GMP compliance check still required before domestic production and sales.
Source:Jul 30, 2026, 07:45 UTC
Hai Xiang Yao Ye's wholly-owned subsidiary Chuan Nan Yao Ye received renewed Veterinary Drug Production License and Veterinary Drug GMP Certificate from Zhejiang Provincial Department of Agriculture and Rural Affairs, valid until May 17, 2027, covering non-sterile active pharmaceutical ingredients (Grade D, florfenicol (2 lines), flunixin meglumine).
Source: